Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report?

Zacks2024-11-30

A month has gone by since the last earnings report for Penumbra (PEN). Shares have added about 6.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2487598462?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/apbC75v0joJeGGZArvqIvw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c","is_english":true,"pubTime":"2024-11-30 00:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2487598462","market":"us","top_or_hot":-1,"title":"Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report?","media":"Zacks","content":"<div>\n<p>A month has gone by since the last earnings report for Penumbra (PEN). Shares have added about 6.7% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue leading up to...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-penumbra-pen-6-7-163158676.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Penumbra (PEN) Up 6.7% Since Last Earnings Report?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-30 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-penumbra-pen-6-7-163158676.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A month has gone by since the last earnings report for Penumbra (PEN). Shares have added about 6.7% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue leading up to...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-penumbra-pen-6-7-163158676.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEN","symbol_name":"Penumbra Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/why-penumbra-pen-6-7-163158676.html","article_id":"2487598462","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/apbC75v0joJeGGZArvqIvw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487598462","pubTimestamp":1732897918,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"A month has gone by since the last earnings report for Penumbra . Shares have added about 6.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Penumbra due for a pullback?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.Penumbra reported third-quarter 2024 adjusted earnings per share of 85 cents, which surpassed the Zacks Consensus Estimate by 23.2%. Adjusted earnings per share improved 26.9% year over year.Penumbra registered revenues of $301 million in the reported quarter, up 11.1% year over year on a reported basis and 10.9% at a constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 1%.Sales in the International segment dropped 1.9% to $74.7 million. Excluding the impact of foreign currency, the unit’s sales were down 2.5% year over ye","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PEN":"Penumbra Inc","NARI":"Inari Medical, Inc."},"translate_title":"为什么Penumbra(PEN)自上次收益报告以来上涨了6.7%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1,"NARI":0.9},"content_text":"A month has gone by since the last earnings report for Penumbra (PEN). Shares have added about 6.7% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue leading up to its next earnings release, or is Penumbra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. \nPenumbra Q3 Earnings Beat, Margins Expand\nPenumbra reported third-quarter 2024 adjusted earnings per share of 85 cents, which surpassed the Zacks Consensus Estimate by 23.2%. Adjusted earnings per share improved 26.9% year over year.\nGAAP earnings were 75 cents per share, a 226% jump from the year-ago GAAP earnings of 23 cents per share.\nQ3 Revenues\nPenumbra registered revenues of $301 million in the reported quarter, up 11.1% year over year on a reported basis and 10.9% at a constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 1%.\nPenumbra's Q3 Results in Detail\nThe company reports under two geographical segments — United States and International.\nPEN recorded revenues of $226.3 million (75.2% of total revenues) in the United States, up 16.2% year over year on a reported basis as well as at CER.\nSales in the International segment dropped 1.9% to $74.7 million. Excluding the impact of foreign currency, the unit’s sales were down 2.5% year over year.\nThe company currently reports its product revenues under two categories — Thrombectomy, and Embolization and Access.\nThe company registered revenues of $204.1 million from sales of Thrombectomy products, up 14% on a reported basis and 13.8% at CER.\nSales of Embolization and Access products totaled $96.9 million, up 5.5% on a reported basis and 5.2% at CER.\nMargin Trend\nIn the reported quarter, Penumbra’s gross profit improved 12.7% year over year to $200.3 million. Gross margin expanded 95 basis points to 66.5% despite an 8.1% rise in the cost of revenues.\nSelling, general and administrative expenses rose 10.9% to $139.7 million. Research and development expenses totaled $25.2 million, up 20.3% year over year. Total operating expenses were $14.9 million, up 12.3% year over year.\nThe company reported adjusted operating margin of 11.7%, a 37-bp expansion year over year.\nFinancial Update\nPenumbra exited the third quarter of 2024 with cash and cash equivalents and marketable investments of $291 million, compared with $339.7 million at the end of the second quarter of 2024.\nUpdated 2024 Guidance\nThe company reiterated its total revenue projection for 2024 in the range of $1.18-$1.20 billion.\nThe company narrowed its expectation for the U.S. thrombectomy franchise growth to the range of 24% to 25% year over year, compared with 23% to 25% expected previously.\nThe Zacks Consensus Estimate for revenues is currently pegged at $1.19 billion.\nThe gross margin and adjusted operating margin expansion guidance for the full year was reiterated at 100-150 and 100-200 basis points, respectively.\nHow Have Estimates Been Moving Since Then?\nIn the past month, investors have witnessed an upward trend in estimates revision.\nThe consensus estimate has shifted 7.78% due to these changes.\nVGM Scores\nCurrently, Penumbra has a great Growth Score of A, a grade with the same score on the momentum front. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.\nOverall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.\nOutlook\nEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Penumbra has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.\nPerformance of an Industry Player\nPenumbra is part of the Zacks Medical - Instruments industry. Over the past month, Inari Medical, Inc. (NARI), a stock from the same industry, has gained 5.4%. The company reported its results for the quarter ended September 2024 more than a month ago.\nInari Medical reported revenues of $153.39 million in the last reported quarter, representing a year-over-year change of +21.4%. EPS of -$0.13 for the same period compares with $0.05 a year ago.\nInari Medical is expected to post a loss of $0.04 per share for the current quarter, representing a year-over-year change of -180%. Over the last 30 days, the Zacks Consensus Estimate has changed +22.9%.\nInari Medical has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nInari Medical, Inc. (NARI) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2487598462"}